Bortezomib is primarily used to treat multiple myeloma, a cancer of plasma cells, and mantle cell lymphoma. These cancers are characterized by the uncontrolled growth of B cells, a type of white blood cell. The drug's efficacy in these conditions has been well documented through numerous clinical trials, showing improvements in progression-free survival and overall response rates.
